Compare IART & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IART | PCRX |
|---|---|---|
| Founded | 1989 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 999.0M |
| IPO Year | 1996 | 2010 |
| Metric | IART | PCRX |
|---|---|---|
| Price | $19.68 | $25.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $14.33 | ★ $30.25 |
| AVG Volume (30 Days) | ★ 900.7K | 479.1K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $4.39 | $6.78 |
| Revenue Next Year | $3.40 | $8.54 |
| P/E Ratio | ★ N/A | $370.43 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $8.70 | $18.80 |
| 52 Week High | $20.26 | $27.64 |
| Indicator | IART | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.53 | 60.51 |
| Support Level | $10.61 | $21.89 |
| Resistance Level | $20.26 | $26.94 |
| Average True Range (ATR) | 0.85 | 0.82 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 85.23 | 56.59 |
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.